Exchange: OTC·Updated 09:35 AM EDT
About ATHJF
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the following segments: ATL1102 and HMBD-002. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The HMBD-002 segment refers to a recombinant, humanised monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.